SCHEMBL4359684

SCHEMBL4359684

NC(=O)c1cc(Oc2ccc(O)c(N)c2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 5/20 0.46
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
MCL1 Q07820 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
BRAF P15056 2/20 0.41
P2RX3 P56373 6/20 0.40
KDR P35968 2/20 0.40
LCK P06239 1/20 0.39
OPRK1 P41145 1/20 0.38
KCNH2 Q12809 1/20 0.38
NR4A1 P22736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364825 0.88 KDM4E (0.44) KDM4EMEN1ALDH1A1GAAMAPT
SCHEMBL4371903 0.83 KDR (0.59) RAF1MEN1KMT2ABRAFKDR
SCHEMBL4369342 0.83 PARP10 (0.54) RAF1MEN1ALDH1A1KMT2ABRAF
SCHEMBL177841 0.83 PARP10 (0.54) RAF1MEN1ALDH1A1GAAMAPT
SCHEMBL400969 0.81 RAF1 (0.47) RAF1BRAFP2RX3KDRGRM5
SCHEMBL1137124 0.81 RAF1 (0.53) RAF1BRAFP2RX3KDROPRK1
SCHEMBL4328009 0.81 RAF1 (0.49) RAF1BRAFP2RX3KDRGRM5
SCHEMBL5764943 0.81 RAF1 (0.47) RAF1BRAFP2RX3KDREPHX2
SCHEMBL4365096 0.80 L3MBTL1 (0.43) RAF1KDM4EMEN1ALDH1A1GAA
SCHEMBL15556982 0.79 CDK8 (0.46) RAF1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531553-B2 Heterocyclic compounds and methods of use AMGEN INC. (US) 2009-05-12 US disclosed
EP-1638954-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC. (US) 2006-03-29 EP disclosed
US-20040209892-A1 Heterocyclic compounds and methods of use U.S. PATENT OPERATIONS 2004-10-21 US disclosed
WO-2004085425-A1 FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS AMGEN INC (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209892-A1 Heterocyclic compounds and methods of use VHL, NQO1, HPGDS RAF1 1846/4885KDM4E 2631/4885MEN1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.